<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930891</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-0802</org_study_id>
    <secondary_id>2009-010187-42</secondary_id>
    <nct_id>NCT00930891</nct_id>
  </id_info>
  <brief_title>Bevacizumab in Extensive Small Cell Lung Cancer</brief_title>
  <acronym>CPC</acronym>
  <official_title>Randomized Phase II-III Study of Bevacizumab 7,5 mg/kg in Combination With Chemotherapy Versus Chemotherapy in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy : PCDE (cisPlatin - Cyclophosphamide - epiDoxorubicin - Etoposide) or PE (cisPlatin - Etoposide)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the fact that a substantial response rate may be obtained in small-cell lung cancers
      (using double-drug chemotherapy: cisplatin-etoposide, PE), a cure remains an exception. More
      aggressive regimens remain controversial and recent attempts at increasing dose-intensity
      have been restricted to patients with a more favourable presentation.

      Bevacizumab is a humanized monoclonal antibody which binds to VEGF (Vascular Endothelial
      Growth Factor). In association with double-drug standard chemotherapies, it has been proven
      that bevacizumab can improve survival of previously untreated advanced non-small-cell lung
      cancers (NSCLC), compared to chemotherapy without bevacizumab). Such promising effects on
      NSCLC deserve to be tested on small-cell lung cancers.

      In this trial (IFCT-0802), standard chemotherapy (PCDE or PE) will be compared to
      experimental treatment (PCDE or PE + bevacizumab 7.5 mg/kg) for previously untreated SCLC
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (complete response + partial response)</measure>
    <time_frame>6 weeks after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response length</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 additional cycles of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 additional cycles of chemotherapy + bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Chemotherapy (PCDE or PE)</intervention_name>
    <description>PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles
PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Treatment (PCDE or PE + bevacizumab)</intervention_name>
    <description>PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression
PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prerandomization Chemotherapy (PCDE or PE)</intervention_name>
    <description>PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles
PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (must be checked at the inclusion, week -8):

          -  Small-Cell Lung Cancer histologically or cytologically proved

          -  Extended disease as defined by Veteran's Administration Lung Cancer Group (VALG)

          -  At least one unidimensionally measurable lesion (RECIST criterion)

          -  Age between 18 and 75 years

          -  Weight loss &lt; 10% for the last three month

          -  Performance Status (PS)≤ 2

          -  Creatininemia &lt; 110 µmol/L and creatinin clearance &gt; 60 mL/min

          -  Neutrophils ≥ 1,500/µL and platelets ≥ 100,000/µL

          -  Bilirubin ≤ 1.5 x normal value

          -  Transaminases, Alkaline Phosphatase ≤ 2.5 x ULN excepted in case of liver metastasis
             (5xULN)

          -  Left ventricular ejection fraction (measured by echocardiographic or isotopic method)
             &gt; 50% if PCDE is planned

          -  Electrocardiogram without uncontrolled coronaropathy

          -  Signed informed consent

        Randomization Criteria (to be checked during the randomization (week 0)):

          -  Partial or complete tumoral response as defined by RECIST

          -  All chemotherapy-induced toxicities decreased to level ≤ 2 as defined by NCI CTC VS 3
             (except for alopecia)

          -  Inclusion criteria concerning creatininemia, clearance, neutrophils, platelets,
             transaminases, alkaline phosphatases and left ventricular ejection fraction must be
             checked again

        Exclusion Criteria:

          -  Non-Small-Cell Lung Cancer or mixed cancer (small-cell / non-small-cell)

          -  Previous antitumoral treatment of the small-cell lung cancer (chemotherapy,
             radiotherapy, immunotherapy, surgery)

          -  Non-extended disease as defined by VALG

          -  Natremia &lt; 125 mmol/L

          -  Hypercalcemia whereas a corrective treatment

          -  Pathology contra-indicating the hyper-hydration

          -  Hemoptysis in the last three months

          -  Tumor invading large vessels or invading the proximal trachea-bronchial tree (visible
             at the medical imagery). Investigator or radiologist must reject tumors adjoining,
             merging or extending to large vessel's lumen (for example : pulmonary artery, superior
             vena cava)

          -  Symptomatic cerebral or meningeal metastasis

          -  Other cancer in progress or medical history of cancer in the five last years (excepted
             basal cell carcinoma or in situ cervical cancer of the uterus.

          -  Important surgical intervention (including surgical biopsy), traumatic lesion during
             28 days before starting the treatment, or anticipation of an important surgical
             intervention during the study

          -  Minor surgical intervention, including implanting permanent catheter during the 24
             hours before the first administration of bevacizumab

          -  Unhealed wound, evolutive gastroduodenal ulcer, fractured bone

          -  Medical history of abdominal fistula, trachea-oesophageal fistula, of another type
             with a severity rank of 4, gastrointestinal perforation or intraabdominal abscess
             during 6 month before inclusion

          -  Ongoing or recent use of aspirin (during 10 days before the first administration of
             bevacizumab) (&gt;325 mg/day) or use of another platelet aggregation inhibitor
             (dipyridamole, ticlopidine, clopidogrel &gt; 75 mg/day), or ongoing or recent use of a
             therapeutic dose (during 10 days before the first administration of bevacizumab) of
             anticoagulant or thrombolytic drugs per os or in parenteral injection. Prophylactic
             use of anticoagulant drug is allowed

          -  Medical history or genetic predisposition to bleeding or coagulopathy

          -  Clinically significative cardiac disease: infarct or CVA during 6 month before
             inclusion, unstable angina, congestive cardiac failure level &gt; II as defined by New
             York Heart Association (NYHA) or cardiac arrythmia needing a specific treatment which
             risk to interfere with the study, or uncontrolled arrythmia.

          -  Known allergy or hypersensibility to monoclonal antibodies (bevacizumab), to chinese
             hamster ovary cells or to any humanized or recombinant antibody

          -  Uncontrolled high blood pressure (systolic pressure &gt; 150 mm Hg and/or diastolic
             pressure &gt; 100 mm Hg), with or without hypotension treatment. Patients presenting an
             high blood pressure are eligibles if their treatment can decrease their blood pressure
             to the values required by the protocol.

          -  Severe ongoing infectious disease or fever &gt; 38.5°C or evidence of any other
             pathology, organic or neurologic functions deterioration, physical examination or
             laboratory result which cause suspicion of a disease which contra-indicate use of any
             studied treatment.

          -  Woman with a positive pregnancy test or who has not made a pregnancy test (unless
             pregnancy risk can be excluded)

          -  Lactating woman

          -  Sexually active woman who don't use hormonal or mechanical contraceptive method or
             sexually active man who has a sexually active partner who don't want to use an
             effective contraceptive method during the course of the study and during the 6 months
             after last treatment administration

          -  Patient who as already been included and treated in the present study

          -  Patient who participate or who has participated in another study during 4 weeks before
             treatment administration

          -  Patient who receive a previous antiangiogenic treatment (experimental or commercial :
             bevacizumab, thalidomide, CP-547632, sunitinib, sorafenib...)

          -  Geographical or psychological condition which not allowed a good comprehension or
             compliance to protocol

          -  Liberty deprived patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis PUJOL, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Annemasse - CH</name>
      <address>
        <city>Ambilly</city>
        <zip>74100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angers - CHU</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Armentières - CH</name>
      <address>
        <city>Armentières</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Besancon - Pneumologie</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre F. Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Pneumologie</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cahors - CH</name>
      <address>
        <city>Cahors</city>
        <zip>46000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chalons-en-Champagne - CH</name>
      <address>
        <city>Chalons-en-Champagne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chauny - CH</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Percy-Armées - Pneumologie</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clermont Ferrand - CHU</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colmar - CH</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH - Compiègne</name>
      <address>
        <city>Compiègne</city>
        <zip>60300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Créteil - CHI</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dijon - CAC</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dijon - CHU</name>
      <address>
        <city>Dijon</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Draguignan - CH</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble - pneumologie</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harfleur - Clinique du Petit Colmoulins</name>
      <address>
        <city>Harfleur</city>
        <zip>76700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Omer - CHI</name>
      <address>
        <city>Helfaut</city>
        <zip>62570</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonzac - CH</name>
      <address>
        <city>Jonzac</city>
        <zip>17500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chartres - CH</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier - Pneumologie</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Longjumeau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital Sainte Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille - CRLCC</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maubeuge - Polyclinique du Parc</name>
      <address>
        <city>Maubeuge</city>
        <zip>59600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meaux - CH</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metz - CHR</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mont de Marsan - CH</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montpellier - CHRU</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mulhouse - CH</name>
      <address>
        <city>Mulhouse</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuilly - Hôpital Américain de Paris</name>
      <address>
        <city>Neuilly</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevers - CH</name>
      <address>
        <city>Nevers</city>
        <zip>58033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nice - CAC</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orléans - CH</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Saint-Antoine - pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Tenon - Pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pau - CH</name>
      <address>
        <city>Pau</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL - Lyon Sud (Pneumologie)</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reims - CHU</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reims - CRLCC</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen - CHU</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Brieuc - CHG</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Nazaire - Centre Etienne Dolet</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Priest en Jarez - ICL</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Quentin - CH</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saverne - CH</name>
      <address>
        <city>Saverne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senlis - CH</name>
      <address>
        <city>Senlis</city>
        <zip>60300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvel Hopital Civil - Pneumologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suresnes - Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thonon les bains</name>
      <address>
        <city>Thonon les bains</city>
        <zip>74200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulon - HIA</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Pneumologie</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulouse - Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tours - CHU</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nancy - CHU</name>
      <address>
        <city>Vandoeuvre lès Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Verdun - CHG</name>
      <address>
        <city>Verdun</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vesoul - CHI</name>
      <address>
        <city>Vesoul</city>
        <zip>70000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ifct.fr</url>
    <description>IFCT official website</description>
  </link>
  <reference>
    <citation>Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, Janicot H, Westeel V, Gameroff S, Genève J, Maraninchi D. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol. 2007 Sep 1;25(25):3945-51.</citation>
    <PMID>17761978</PMID>
  </reference>
  <reference>
    <citation>Pujol JL, Daurès JP, Rivière A, Quoix E, Westeel V, Quantin X, Breton JL, Lemarié E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst. 2001 Feb 21;93(4):300-8.</citation>
    <PMID>11181777</PMID>
  </reference>
  <reference>
    <citation>Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009 Dec 10;27(35):6006-11. doi: 10.1200/JCO.2009.23.7545. Epub 2009 Oct 13.</citation>
    <PMID>19826110</PMID>
  </reference>
  <results_reference>
    <citation>Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, Chatellain P, Barre P, Jeannin G, Mourlanette P, Derollez M, Herman D, Renault A, Dayen C, Lamy PJ, Langlais A, Morin F, Zalcman G; French Cooperative Thoracic Intergroup (IFCT); French Cooperative Thoracic Intergroup IFCT. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†. Ann Oncol. 2015 May;26(5):908-14. doi: 10.1093/annonc/mdv065. Epub 2015 Feb 16.</citation>
    <PMID>25688059</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2009</study_first_submitted>
  <study_first_submitted_qc>July 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extensive-Disease Small-Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

